Biopharmaceutical and Biomedicine Market, by Product Type (Biopharmaceutical, Nano medicine, Gene Therapy, Bioinformatics, and Molecular Enzymes & Kits Market), and by Region - Global Industry Insights, and Forecast, 2022 - 2028

Biopharmaceutical and Biomedicine Market, by Product Type (Biopharmaceutical, Nano medicine, Gene Therapy, Bioinformatics, and Molecular Enzymes & Kits Market), and by Region - Global Industry Insights, and Forecast, 2022 - 2028

Biopharmaceuticals has emerged as one of the key segments with immense growth potential in the healthcare sector. Rising demand for effective treatment and rise in per capita healthcare expenditure has led to double digit revenue growth for industry players in the recent past. The industry offers lucrative growth opportunities, since most of these products still have low penetration rate. The market is expected to gain further traction, with evolving treatment archetypes and rapid technological innovation such as cell therapy and regenerative medicines.
Market Dynamics
Launches and approvals of novel biopharmaceutical and biomedicine products is expected to drastically drive growth of global biopharmaceutical and biomedicine market in the near future. For instance, in 2021, Sanofi S.A. received U.S. FDA approval for its Adlyxin ((lixisenatide) injection. Adlyxin is indicated to improve blood sugar levels among adults suffering from type 2 diabetes. In 2021, Johnson & Johnson received U.S. FDA approval for its Stelara (Ustekinumab), indicated for the treatment of adults suffering from moderately to severely active crohn’s disease. In 2021, CSL Behring received U.S. FDA approval for its IDELVION, Coagulation Factor IX (Recombinant), Albumin Fusion Protein. IDELVION is indicated for the treatment of Hemophilia B among children and adults. In 2017, Nanostring Technologies, Inc. launched nCounter platform advances as well as new panels expanding the company’s presence in immuno-oncology and 3D biology research. In 2015, Celltrion Healthcare Co., Ltd. launched its Remsima (infliximab), a biosimilar monoclonal antibody (mAb) in Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden, and the UK. Furthermore, increasing collaborations and acquisitions by major key players in market is also expected to create lucrative environment for growth of market. For instance, in 2021, Biocon Ltd., wholly owned subsidiary of Biocon SA, collaborated with Laboratorios PiSA S.A. de C.V—a Mexico-based company—for the co-development and commercialization of generic recombinant human insulin (rh-insulin) in the U.S. market. In 2021, AbbVie Inc. acquired all rights from Boehringer Ingelheim (BI) for Risankizumab (BI 655066). Risankizumab is an anti-IL-23 monoclonal biologic antibody for psoriasis. Company is also evaluating the product for other indications such as Crohn’s disease, asthma, and psoriatic arthritis. Currently, it is in clinical phase 3.
Key features of the study:
This report provides in-depth analysis of biopharmaceutical and biomedicine market and provides market size (US$ Billion) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global biopharmaceutical and biomedicine market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include Amgen Inc., F. Hoffmann-La Roche AG, Novartis AG, Johnson & Johnson, Pfizer, Inc., Sanofi S.A., Eli Lilly and Company, AbbVie Inc., Novo Nordisk A/S, Bristol - Myers Squibb, NanoString Technologies, Inc., Qiagen N.V., Celgene Corporation, and Affimed N.V.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global biopharmaceutical and biomedicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the biopharmaceutical and biomedicine market
Detailed Segmentation:
Global Biopharmaceutical and Biomedicine Market, By Product Type :
Biopharmaceutical
Monoclonal Antibodies Market
Vaccines
Recombinant Human Insulin
Human Growth Hormone
Erythropoietin
Interferon
Colony Stimulating Factor
Blood Factors
Fusion Protein
Others
Nanomedicine
Cell & Gene Therapy
Bioinformatics
Molecular Enzymes & Kits Market
Global Biopharmaceutical and Biomedicine Market, By Application:
Therapeutics
Diagnostics
Research and Development
Global Biopharmaceutical and Biomedicine Market, By Geography:
North America
By Product Type :
Biopharmaceutical
Monoclonal Antibodies Market
Vaccines
Recombinant Human Insulin
Human Growth Hormone
Erythropoietin
Interferon
Colony Stimulating Factor
Blood Factors
Fusion Protein
Others
Nanomedicine
Cell & Gene Therapy
Bioinformatics
Molecular Enzymes & Kits Market
By Application:
Therapeutics
Diagnostics
Research and Development
By Country:
U.S.
Canada
Europe
By Product Type :
Biopharmaceutical
Monoclonal Antibodies Market
Vaccines
Recombinant Human Insulin
Human Growth Hormone
Erythropoietin
Interferon
Colony Stimulating Factor
Blood Factors
Fusion Protein
Others
Nanomedicine
Cell & Gene Therapy
Bioinformatics
Molecular Enzymes & Kits Market
By Application:
Therapeutics
Diagnostics
Research and Development
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Product Type :
Biopharmaceutical
Monoclonal Antibodies Market
Vaccines
Recombinant Human Insulin
Human Growth Hormone
Erythropoietin
Interferon
Colony Stimulating Factor
Blood Factors
Fusion Protein
Others
Nanomedicine
Cell & Gene Therapy
Bioinformatics
Molecular Enzymes & Kits Market
By Application:
Therapeutics
Diagnostics
Research and Development
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Product Type :
Biopharmaceutical
Monoclonal Antibodies Market
Vaccines
Recombinant Human Insulin
Human Growth Hormone
Erythropoietin
Interferon
Colony Stimulating Factor
Blood Factors
Fusion Protein
Others
By Application:
Therapeutics
Diagnostics
Research and Development
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
By Product Type :
Biopharmaceutical
Monoclonal Antibodies Market
Vaccines
Recombinant Human Insulin
Human Growth Hormone
Erythropoietin
Interferon
Colony Stimulating Factor
Blood Factors
Fusion Protein
Others
By Application:
Therapeutics
Diagnostics
Research and Development
By Country:
GCC
Israel
Rest of Middle East
Africa
By Product Type :
Biopharmaceutical
Monoclonal Antibodies Market
Vaccines
Recombinant Human Insulin
Human Growth Hormone
Erythropoietin
Interferon
Colony Stimulating Factor
Blood Factors
Fusion Protein
Others
By Application:
Therapeutics
Diagnostics
Research and Development
By Country:
Central Africa
South Africa
North Africa
Company Profiles
Amgen Inc.*
Company Overview
Product Portfolio
Financial Performance
Recent Developments
Key Strategies
F. Hoffmann-La Roche AG
Novartis AG
Johnson & Johnson
Pfizer, Inc.
Sanofi S.A.
Eli Lilly and Company
AbbVie Inc.
Novo Nordisk A/S
Bristol - Myers Squibb
NanoString Technologies, Inc.
Qiagen N.V.
Celgene Corporation
Affimed N.V.
“*” marked represents similar segmentation in other categories in the respective section.